Watson Gets $35 Million From GSK In Wellbutrin XL Patent Dispute
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm will receive one-time payment from GlaxoSmithKline to settle claims the Wellbutrin marketer infringed its bupropion patent.